Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study-Reference-Cited by-同舟云学术

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

Published:2022-02 Issue:2 Volume:6 Page:e12674
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Lentz Steven R.^ORCID,Kavakli Kaan,Klamroth Robert,Misgav Mudi,Nagao Azusa,Tosetto Alberto^ORCID,Jørgensen Pernille Juul,Zak Marek,Nemes Laszlo

Funder

Novo Nordisk

Publisher

Elsevier BV

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12674

Reference27 articles.

1. WFH guidelines for the management of hemophilia;Srivastava;Haemophilia,2020

2. Extended half‐life recombinant products in haemophilia clinical practice ‐ expectations, opportunities and challenges;Chowdary;Thromb Res,2020

3. Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A;Tiede;J Thromb Haemost,2013

4. N8‐GP: a new extended half‐life recombinant factor VIII product for hemophilia A;Chowdary;J Thromb Haemost,2020

5. An overview of the pathfinder clinical trials program: long‐term efficacy and safety of N8‐GP in patients with hemophilia A;Matsushita;J Thromb Haemost,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies;Research and Practice in Thrombosis and Haemostasis;2024-02

2. Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal;Research and Practice in Thrombosis and Haemostasis;2024-02

3. Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: post hoc analysis of phase III trials using patient-reported outcomes;Therapeutic Advances in Hematology;2024-01

4. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results;Journal of Thrombosis and Haemostasis;2023-11

5. Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey;Patient Preference and Adherence;2023-11